Lenient Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2020
- Revenue Growth 131.25%
- Profit Growth 104.21%
- Ebitda -131.27%
- Net Worth 0.59%
- Total Assets 38.35%
About Lenient Pharmaceuticals
Lenient Pharmaceuticals Private Limited (LPPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 January 2015 and has a history of Ten years and one month. Its registered office is in Delhi, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Aakash Srivastava, Ankita Srivastava, and Inderjeet Rawat serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51101DL2015PTC274986
-
Company No.
274986
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Jan 2015
-
Date of AGM
30 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Lenient Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Inderjeet Rawat
|
Director | 16-Sep-2020 | Current |
|
Aakash Srivastava
|
Director | 16-Sep-2020 | Current |
|
Ankita Srivastava
|
Director | 05-Jan-2015 | Current |
Financial Performance of Lenient Pharmaceuticals.
Lenient Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 131.25% increase. The company also saw a substantial improvement in profitability, with a 104.21% increase in profit. The company's net worth moved up by a moderate rise of 0.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lenient Pharmaceuticals?
In 2017, Lenient Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Macligent LlpAakash Srivastava and Ankita Srivastava are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lenient Pharmaceuticals?
Unlock and access historical data on people associated with Lenient Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lenient Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lenient Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
